Best Biopharma Outsourcing Companies in Spain
The 129 best Biopharma Outsourcing companies in Spain in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: UQUIFA Group.
Spain's Biopharma Outsourcing sector isn't a footnote anymore. This directory ranks 129 tracked companies operating in Spain by disclosed equity funding and recent funding momentum, and the numbers tell a clear story about where the capital is concentrating. Total disclosed funding across the cohort sits at $85M, with Uquifa Group pulling hard at the front on $42M, well clear of Leanbio ($6M) and ZeClinics ($5M). No unicorns yet, but the funding distribution is tightening around a handful of specialists. Globally, the market was valued at roughly $28.7B in 2024 and is forecast to reach $112.3B by 2032, compounding at 5.8% annually, driven by biologics demand and rising drug development costs. That tailwind is real, and Spain's CRO and CDMO ecosystem is positioned to catch more of it.
So what should you watch this cycle? Clinical trial outsourcing and operational resilience are the two themes pulling the most coverage right now, and regulatory compliance pressure is only adding urgency. Most active investors here include the EIC Fund, Europa, and Caixa Capital Risc, which tells you the funding pipeline is still heavily institutional and EU-linked. I'd argue that dynamic keeps deal sizes modest but keeps the pipeline moving steadily. Median install growth across outsourcing-adjacent apps is running at roughly 13% year-on-year, a proxy for how fast demand-side activity is accelerating. The infrastructure is building.
- ResearchAndMarkets.com
Our analysis of 100 Biopharma Outsourcing companies
$10.3b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in Spain
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | UQUIFA Group CDMO company manufacturing APIs and intermediates | $42M | 15 mo ago | Acquired | — | 28 | WordPressMySQLPHP+23 | — | 1 partnership · 1 award |
| 2 | Vivia Biotech Developer of precision medicine test for hematologic cancers | $8M | 170 mo ago | Series A | Andres Ballesteros CEO | — | — | 69 patents Ex vivo engineered bite‑activated immune cells and CAR‑T therapies for cancer immunotherapy | — |
| 3 | Leanbio Manufacturer of biopharmaceutical product in immunotherapy | $6M | 26 mo ago | Acquired | Andreu Soldevila CEO | 15 | WordPressMySQLPHP+16 | 10 patents Targeted enzyme delivery using liposomal pharmaceutical formulations | — |
| 4 | ZeClinics Provider of CRO developing zebrafish models for toxicity studies | $5M | 44 mo ago | Funding Raised | — | 38 | WordPressMySQLPHP+24 | 3 patents Recombinant DNA methods for producing heterologous proteins for tissue regeneration | 2 launchs · 1 expansion |
| 5 | BDI biotech R&D center engaged in the development of microbial strains | $5M | 64 mo ago | Seed | Pablo Gutierrez CEO | 50 | WordPressMySQLPHP+31 | — | — |
| 6 | Histocell Provider of products and services in cell therapy for regenerative medicine | $3M | 72 mo ago | Series A | — | 24 | Cart FunctionalityWordPressMySQL+19 | 110 patents Regenerative biomaterial scaffolds and antioxidant hydrogel dressings for oral and skin wound healing | — |
| 7 | Nanoligent Provider of preclinical services for the development of oncology drugs | $2M | 8 mo ago | Series A | M Rodriguez Co-Founder | 9 | — | 8 patents Protein scaffold nanoconjugates for targeted therapeutic delivery | — |
| 8 | Biointaxis Biotechnology company that offers pre-clinical research and gene therapy products | $2M | 19 mo ago | Funding Raised | — | 7 | — | — | — |
| 9 | Nanomol Technologies Provider of particle design, nanoformulation technologies, and cGMP particle characterization services | $2M | 41 mo ago | Funding Raised | Santi Sala Vergés Co-Founder & CEO | — | — | 3 patents Lipid-based vesicle formulations for enzyme delivery and glucose-derived surfactant systems | 1 partnership |
| 10 | Zebrafish Lab Zebrafish based services for preclinical and environmental applications | $2M | 81 mo ago | Funding Raised | Roberto Diez-Martinez Co-Founder & CEO | — | — | — | — |
| 11 | Science4Tech Provider of trial designing, launch, enrollment & feedback services for pharmaceutical industry | $2M | 48 mo ago | Seed | Jordi Guitart CEO | 39 | — | — | — |
| 12 | Specipig CRO Specializing in Swine Models | $605K | 123 mo ago | Seed | Jaume Amat Riera CEO | 18 | — | — | — |
| 13 | AtG CRO focused on providing drug discovery and development services to metabolic disease | $568K | 47 mo ago | Seed | Oriol Casanovas Co-Founder | 5 | — | — | 1 job opening |
| 14 | Biobide CRO specializing in Zebrafish toxicity and efficacy assays | $432K | 33 mo ago | Funding Raised | Andoni Cruz Co-Founder | 17 | — | — | — |
| 15 | MedBioInformatics Solutions Provider of NLP and AI solutions for life science data analysis. | $429K | 60 mo ago | Funding Raised | Janet Piñero Co-Founder | 9 | WordPress Block EditorWordPressMySQL+20 | — | — |
| 16 | i+Med Biomedical engineering company specializing in the research, development, and manufacturing of biomedical… | $402K | 77 mo ago | Funding Raised | Manu Munoz CEO | 67 | WordPressMySQLPHP+16 | — | — |
| 17 | MolDrug AI Systems Provider of computational chemistry and molecular modeling services for drug discovery | $390K | 60 mo ago | Funding Raised | Rafael Gozalbes CEO | — | — | — | — |
| 18 | IDIVAL Provider of research, clinical trial, and training services | $287K | 65 mo ago | Funding Raised | — | — | WordPressMySQLPHP+24 | — | — |
| 19 | Nostrum Biodiscovery Manufacturer of drug discovery and development services | $141K | 89 mo ago | Funding Raised | Modesto Orozco Co-Founder | — | WordPressMySQLPHP+25 | 2 patents Repurposed antipsychotic oncology therapy and p38α autophosphorylation kinase inhibitors | 2 awards |
| 20 | Bioithas Research center specializing in the management of licenses, patents, and other sanitary registries for direct… | $111K | 78 mo ago | Funding Raised | Vicente Navarro Founder & CEO | — | Cart FunctionalityShopifyVisa+24 | 15 patents Probiotic-based therapeutic formulations targeting alopecia (hair loss) treatment. | 1 award |
| 21 | Enzymlogic CRO working on enzymology and binding kinetics analysis for small-molecule drug discovery programs for… | $111K | 78 mo ago | Seed | Patricia Alfonso San-Segundo Co-Founder & Chief Scientific Officer | 10 | — | 8 patents Kinetic profiling of drug candidates using analytical bioassay methods | — |
| 22 | StemTek Therapeutics Stem cell focused research services for drug development for cancer treatment | $108K | 109 mo ago | Deadpooled | Angel Garcia Martin Co-Founder & CEO | — | — | 4 patents 3D culture techniques for generating cancer stem cell spheroids | — |
Top 12 Biopharma Outsourcing companies in Spain
#1
Acquired · Barcelona, Catalonia · founded 1936 · 28 employees$42.5Mraised▾
CDMO company manufacturing APIs and intermediates. It supports customers through its new chemical entity programs from pre-clinical stages to commercial production. It also offers comprehensive chemical manufacturing capabilities such as hydrogenation, chlorination, and micronization.
#2
Series A · Barcelona, Catalonia · founded 2017 · 9 employees$2.5Mraised▾
Provider of preclinical services for the development of oncology drugs
- Oct 2025Series A$13.9M
- Sep 2022Seed—
- Feb 2022Seed$1.1M
#3
Funding Raised · Barcelona, Catalonia · founded 2017 · 7 employees$2.4Mraised▾
Developer of genomic treatments and technologies intended for neurological diseases. The company develops innovative gene therapy for the treatment of Friedreich's ataxia, a rare neurological disease, enabling patients with Friedreich's ataxia, a rare neurodegenerative disease for which there is currently no treatment.
- Oct 2024Grant (prize money)$2.3M
- Jul 2023Grant (prize money)$81.9K
#4
Acquired · Barcelona, Catalonia · founded 2014 · 15 employees$6.3Mraised▾
Manufacturer of biopharmaceutical product in immunotherapy. The company has developed recombinant protein in E. coli, CHO mammalian cell line, P. pastoris and S. cerevisiae. The company has developed a platform for upstream (USP) and downstream (DSP) of microbial and mammalian cell cultures and purification of a biotherapeutics. It also developed a platform for the analysis and formulation of protein therapeutics.
- Apr 2024Angel$6.3M
- Mar 2021Grant (prize money)$1.7M
#5
Funding Raised · Barcelona, Catalonia · founded 2013 · 38 employees$5.2Mraised▾
Provider of CRO developing zebrafish models for toxicity studies. The company is supported by University Pompeu Fabra (UPF) and incubated at Barcelona Biomedicine Research Park (PRBB). Services offered by the company include toxicity, efficacy, and genesis assay on zebrafish (using CRISPR/Cas9 technology). Their proprietary models have been licensed by Harvard, MIT, and Broad Institute.
- Oct 2022Grant (prize money)$108.2K
- Jan 2020Grant (prize money)$502K
- Oct 2019Grant (prize money)$274.4K
- Jun 2019Grant (prize money)$180.2K
#6
Funding Raised · Barcelona, Catalonia · founded 2010$2.3Mraised▾
Provider of particle design, nanoformulation technologies, and cGMP particle characterization services. It delivers advanced solutions and technologies to obtain high-added value products through particle design and nanoformulation. It is active in collaborative projects, applying micro and nanotechnology to biomedical and healthcare purposes. The company offers contract analysis on particle characterization, providing high-added value and cGMP services for various materials. The DELOS platform is used for nanoformulation and drug delivery, adding value to drugs and healthcare products.
- Jan 2023Grant (prize money)$523.1K
- Oct 2021Grant (prize money)$26.7K
- Mar 2021Grant (prize money)$1.1M
- Dec 2017Grant (prize money)$149.9K
#7
Seed · Barcelona, Catalonia · founded 2019 · 39 employees$2.1Mraised▾
Developer of a digital platform designed to accelerate the results of clinical trials for the benefit of patients. The company's services collect data from all stages and agents involved in the clinical trial process, and they provide value-added services supported by data-driven SaaS technology and application to improve clinical testing stages under strict scientific rigor and in compliance with regulatory framework, enabling physicians and other healthcare professionals to store information collected from multiple sources and transform data into potent dashboards for decision-making.
- 2022Seed$2.1M
#8
Series A · Derio, Basque Country · founded 2005 · 24 employees$3.5Mraised▾
HistoCell is a spin-off from the University of the Basque Country and engages in developing new technologies in regenerative medicine. The company uses Adult Mesenchymal Stem Cells (AMSCs) and bioactive materials (scaffolds) as their key technology and focuses n these therapeutic areas bone regeneration, advanced wound healing, inflammatory diseases, neurodegeneration, and ischemia or lung therapy. The product line of the company includes Wharton Gel complex (Cosmetic ingredient with regenerative property), medical device (Rexocare-wound dressing with antioxidant properties, Histogel (Natural product with tissue regeneration properties), Histobone (Engineered synthetic bone matrix of structured porous monetite (Calcium phosphate derivate) for osseous regeneration). Additionally, the company also offers services in the manufacturing of cell therapy products for therapeutic use.
- Jun 2020Grant (prize money)$944.1K
- Sep 2018Series A$3.5M
- Jul 2017Grant (prize money)$58.8K
- Feb 2017Grant (prize money)$53.8K
#9
Seed · Valladolid, Castile and Leon · founded 2014 · 50 employees$4.8Mraised▾
BDI Biotech is a biotechnology company offering biopharma drug development services through its expertise in product expression under different platforms (yeast, bacteria, and fungi), upstream and downstream process development, scale-up and contract manufacturing. The company has two main divisions namely BDI Health and BDI Food. The company has developed a patented and proprietary antigen-display nanoplatforms based on Virus-Like Particles (VLPs). These VLPs are empty and non-infectious structures that mimic real viruses and are capable of inducing both humoral and cellular responses. They have capabilities to incorporate pathology-associated antigens into VLPs for generating chimeric nanoparticles (Ch-VLPs). The company has developed CerviVax, an immunotherapeutic vaccine focused on the treatment of HPV-16/HPV-18 (Human Papilloma Virus) infections and cervical dysplasia which has shown promising results in in-vivo efficacy and POC studies.
- Jan 2021Grant (prize money)—
- Jan 2018Seed$4.8M
#10
Funding Raised · San Sebastian de los Reyes, Community of Madrid · founded 2005 · 17 employees$431.5Kraised▾
Biobide is a CRO, offering standard assays and custom-made solutions for Zebrafish based toxicity and efficacy testing services (GLP compliant) to the pharmaceutical, biotech, chemical, cosmetic and nutraceutical companies. Biobide's Zebrafish service portfolio includes target validation, disease model generation, toxicity assays such as multitox, acutetox, teratotox, cardiotox, hepatotox, ototox, ecotox and behavioral alteration assays and efficacy assays for drugs targeting cancer, CNS, cardiovascular, metabolic and orphan diseases.
- Sep 2023Grant (prize money)$431.5K
#11
Series A · Tres Cantos, Community of Madrid · founded 2007$7.5Mraised▾
Developer of precision medicine test for hematologic cancers. It is focused on analyzing the effect of existing drugs directly on a patient’s standard biological sample such as blood or bone marrow using its proprietary ExviTech technological platform. It has also developed medicine test for the treatment of hematological malignancies like leukemia and multiple myeloma. The company partners with pharmaceutical & biotechnology companies to provide precision medicine capabilities for patient center drug development and biomarker discovery.
#12
Funding Raised · Noain, Navarre · founded 2015$2.3Mraised▾
The Zebrafish Lab is a preclinical CRO developing and commercializing in vivo zebrafish assays for evaluating adverse side effects of new drug compounds. Apart from the pharma and the biotech industries, their services also cater to the environment, natural product, nutraceutical, agrochemical, food, cosmeceutical and skin care industries. Their offering includes a wide range of Zebrafish models namely, Zebratoxifish, Zebraoncofish, Zebrabactofish, Zebraneurofish, Zebraeffifish, Zebragenefish, and Zebraenvirofish to study the toxicity, mechanism of action, gene expression and several other effects of candidates under evaluation. They also offer their services for the development of custom Zebrafish models as per client requirements. They claim to be the first ever to reproduce a human infectious disease in zebrafish, which can be used for the evaluation of antimicrobial agents.
- Aug 2019Grant (prize money)$2.2M
- Jan 2017Grant (prize money)$53.5K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Spain
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,045 Spain-affiliated papers.
- Universidad Internacional De La Rioja128
- Consejo Superior de Investigaciones Científicas40
- Universidad Complutense de Madrid29
- Universidade de Santiago de Compostela27
- University of Córdoba26
- Population1→5
- Flow cytometry1→5
- Mutant1→4
- DNA damage3→4
- Gene1→15
- Agriculture1→15
- Health benefits2→9
- Germplasm1→8
- In vivo2→8
- Agriculture2→15
- Context (archaeology)1→13
- Antibiotic resistance2→11
- Antimicrobial1→9
- Production (economics)1→9
Where biotechnology is researched across Spain
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.